Answers are grounded in this paper and cite their sources.
Illustration reveals systemic short-chain fatty acid levels in myeloma patients pre and post-CAR T-cell therapy, suggesting a link to therapy outcomes.
Supplementary Figure S4 illustrates the pre and post-CAR T-cell infusion systemic short-chain fatty acid profiles in multiple myeloma patients, specifically detailing levels of acetate, propionate, butyrate, isobutyrate, and formate.
No takes yet. Share an insight, caveat, or question.
Uribe‐Herranz et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: